This NIDA grant is for accelerating the development of new medications to treat Substance Use Disorders (SUDs). The Grand Opportunity in Medications Development (U01) aims to fund high-impact preclinical and/or clinical research projects that can quickly yield results to advance treatments closer to FDA approval. This short-term cooperative agreement, funded for up to three years with up to $5 million annually, involves close monitoring and significant scientific involvement from NIDA staff. It is designed to support critical medications development studies that are not feasible under traditional grant mechanisms, ensuring rapid progress in SUD treatment innovation.
Opportunity ID: 343339
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-202 |
| Funding Opportunity Title: | Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 01, 2022 |
| Last Updated Date: | Jan 03, 2025 |
| Original Closing Date for Applications: | Sep 01, 2025 |
| Current Closing Date for Applications: | Jan 03, 2025 |
| Archive Date: | Feb 02, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $5,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments County governments Independent school districts City or township governments Small businesses State governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| updated close date | Jan 03, 2025 | |
| Sep 01, 2022 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-202 |
| Funding Opportunity Title: | Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 01, 2022 |
| Last Updated Date: | Jan 03, 2025 |
| Original Closing Date for Applications: | Sep 01, 2025 |
| Current Closing Date for Applications: | Jan 03, 2025 |
| Archive Date: | Feb 02, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $5,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments County governments Independent school districts City or township governments Small businesses State governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-202 |
| Funding Opportunity Title: | Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 01, 2022 |
| Last Updated Date: | Sep 01, 2022 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 01, 2025 |
| Archive Date: | Oct 07, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $5,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Small businesses State governments Public and State controlled institutions of higher education For profit organizations other than small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Related Documents
Folder 343339 Full Announcement-PAR-22-202 -> PAR-22-202-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00276643 | Sep 03, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00277965 | Nov 04, 2022 | Jan 24, 2025 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289215 | Nov 27, 2024 | Jan 04, 2025 | View |
Package 1
Mandatory forms
343339 RR_SF424_5_0-5.0.pdf
343339 PHS398_CoverPageSupplement_5_0-5.0.pdf
343339 RR_OtherProjectInfo_1_4-1.4.pdf
343339 PerformanceSite_4_0-4.0.pdf
343339 RR_KeyPersonExpanded_4_0-4.0.pdf
343339 PHS398_ResearchPlan_4_0-4.0.pdf
343339 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343339 RR_Budget_3_0-3.0.pdf
343339 RR_SubawardBudget30_3_0-3.0.pdf
343339 PHS398_ModularBudget_1_2-1.2.pdf
343339 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
343339 RR_SF424_5_0-5.0.pdf
343339 PHS398_CoverPageSupplement_5_0-5.0.pdf
343339 RR_OtherProjectInfo_1_4-1.4.pdf
343339 PerformanceSite_4_0-4.0.pdf
343339 RR_KeyPersonExpanded_4_0-4.0.pdf
343339 PHS398_ResearchPlan_5_0-5.0.pdf
343339 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343339 RR_Budget_3_0-3.0.pdf
343339 RR_SubawardBudget30_3_0-3.0.pdf
343339 PHS398_ModularBudget_1_2-1.2.pdf
343339 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
343339 RR_SF424_5_0-5.0.pdf
343339 PHS398_CoverPageSupplement_5_0-5.0.pdf
343339 RR_OtherProjectInfo_1_4-1.4.pdf
343339 PerformanceSite_4_0-4.0.pdf
343339 RR_KeyPersonExpanded_4_0-4.0.pdf
343339 PHS398_ResearchPlan_5_0-5.0.pdf
343339 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343339 RR_Budget_3_0-3.0.pdf
343339 RR_SubawardBudget30_3_0-3.0.pdf
343339 PHS398_ModularBudget_1_2-1.2.pdf
343339 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
